Originally developed to treat diabetes, SGLT2 inhibitors are potentially groundbreaking in slowing the progression of chronic kidney disease (CKD). Dr. Robert Kossmann, Executive Vice President, Global Head of Renal Therapies, and Chief Medical Officer of Fresenius Medical Care North America joins Field Notes to examine how this class of drug can be used to intervene earlier with patients and is a key tool within value-based care.